Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

GLMD
Galmed Pharmaceuticals Ltd.
stock NASDAQ

At Close
Sep 15, 2025 3:59:30 PM EDT
1.46USD-3.311%(-0.05)79,560
1.46Bid   1.50Ask   0.04Spread
Pre-market
Sep 15, 2025 8:53:30 AM EDT
1.48USD-1.980%(-0.03)5,803
After-hours
Sep 15, 2025 4:46:30 PM EDT
1.47USD+0.753%(+0.01)1,541
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
07:32AM EST  Galmed Announces New Patents For Aramchol And Its Meglumine Salt   Benzinga
07:31AM EST  Galmed Continues to Drive Innovation with Three New US Patents Granted for   PR Newswire
Jan 10, 2022
07:46AM EST  Galmed Announces Results Of Phase 1 Study Of Amilo-5MER Demonstrating Safety And Tolerability   Benzinga
07:33AM EST  Galmed Announces Positive Results Of Phase 1 Study Of Amilo-5MER In Healthy Volunteers   RTTNews
07:31AM EST  Galmed announces positive results of Phase 1 study of Amilo-5MER   PR Newswire
Nov 8, 2021
07:34AM EST  Galmed Pharma Q3 Loss/shr Narrows To $0.31 From $0.32 Prior Year   RTTNews
07:33AM EST  Galmed Pharmaceuticals Q3 EPS $(0.31) Beats $(0.36) Estimate   Benzinga
07:33AM EST  Galmed Announces Data From Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect On Fibrosis Improvement   Benzinga
07:30AM EST  Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label   PR Newswire
07:22AM EST  Galmed Announces New Positive Data From Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect On Fibrosis Improvement   Benzinga
07:18AM EST  Galmed Announces New Positive Data From Open-Label Part Of The ARMOR Phase 3 Study   RTTNews
07:02AM EST  Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part   PR Newswire
05:51AM EST  Shares of Alzheimer's Drug Stocks AC Immune, Galamed Pharma, Annovis Bio Higher After Comments by AC Immune CEO on Sunday that Number of Alzheimer's Cases Could Triple by 2050   Benzinga
05:50AM EST  Shares of Alzheimer's Drug Stocks AC Immune, Galamed Pharma, Annovis Bio Higher After Comments by AC Immune CEO on Sunday   Benzinga
05:06AM EST  Earnings Scheduled For November 8, 2021   Benzinga
Nov 1, 2021
10:18AM EDT  Galmed Announces Positive Results From First 16 Patients In Open-Label Part Of ARMOR Study On NASH   RTTNews
10:13AM EDT  Galmed Announces Results From First 16 Patients In Open-Label Part Of ARMOR Study   Benzinga
10:11AM EDT  Galmed Announces Positive Results from First 16 Patients in Open-Label Part of   PR Newswire
Oct 11, 2021
08:29AM EDT  Galmed : Results Of Phase 2b ARREST Trial Of Aramchol Published In Nature Medicine   RTTNews
08:06AM EDT  Galmed Pharmaceuticals Announces Results Of Its Phase 2b ARREST Trial Of Aramchol Published In Nature Medicine   Benzinga
08:01AM EDT  Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature   PR Newswire
Aug 19, 2021
11:49AM EDT  Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action   Benzinga
08:14AM EDT  Galmed Pharmaceuticals Announces Publication In "The Journal of Autoimmunity" For Its IND Ready, Amilo-5MER   Benzinga
08:08AM EDT  Galmed Says Amilo-5MER Suppresses Chronic Inflammations In Broad Spectrum Of Animal Models Of Inflammatory Diseases   RTTNews
08:02AM EDT  Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity"   PR Newswire
Aug 16, 2021
08:13AM EDT  MHRA Agrees With Galmed's Plan To Use Aramchol Meglumine In Phase 3 ARMOR Study   RTTNews
08:01AM EDT  MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized   PR Newswire
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
07:27AM EDT  Galmed Pharma Q2 Loss/shr $0.33 Vs. Loss/shr $0.26 Prior Year   RTTNews
07:22AM EDT  Galmed Pharmaceuticals Q2 EPS $(0.33) Beats $(0.38) Estimate   Benzinga
07:01AM EDT  Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021   PR Newswire
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 2, 2021
09:26AM EDT  Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial   Benzinga
08:02AM EDT  Galmed Pharmaceuticals Ltd. (GLMD) said that the FDA agreed with its plan to use Aramchol meglumine in its Phase 3 ARMOR study without the need to conduct additional nonclinical and clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine.   RTTNews
07:39AM EDT  FDA Says Galmed Can Proceed With Its Proposed Clinical Studies With Aramchol Meglumine; Stock Up   RTTNews
07:31AM EDT  Galmed Pharmaceuticals Says FDA Agrees With Co's Plan To Use Aramchol Meglumine In Randomized Double-Blind Placebo-Controlled Part Of Phase 3 ARMOR Study   Benzinga
07:31AM EDT  FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized   PR Newswire
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 29, 2021
08:31AM EDT  Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and   PR Newswire
May 17, 2021
10:10AM EDT  Canaccord Genuity Maintains Buy on Galmed Pharmaceuticals, Raises Price Target to $21   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
07:53AM EDT  Galmed Pharmaceuticals Q1 EPS $(0.38) Beats $(0.39) Estimate   Benzinga
07:52AM EDT  Galmed Pharma Q1 Net Loss $8.9 Mln Or $0.38/Shr Vs Loss Of $6.1 Mln Or $0.29/Shr Last Year   RTTNews
07:51AM EDT  Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021   PR Newswire
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
08:31AM EDT  Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and   PR Newswire
May 3, 2021
09:42AM EDT  Galmed Announces Approval Of IND Application In China For Aramchol For Treatment Of NASH & Fibrosis   RTTNews
08:31AM EDT  Galmed Announces Approval Of IND Application In China For Aramchol For Treatment Of NASH & Fibrosis In Global Phase 3 ARMOR Registrational Study   Benzinga
08:31AM EDT  Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study   PR Newswire
Mar 19, 2021
06:23AM EDT  HC Wainwright & Co. Maintains Buy on Galmed Pharmaceuticals, Lowers Price Target to $25   Benzinga
Mar 18, 2021
08:49AM EDT  Galmed Pharmaceuticals shares were trading lower after the company reported worse-than-expected Q4 EPS results.   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
07:23AM EDT  Galmed Pharma Q4 Net Loss $10.3 Mln Or $0.48/Shr Vs Loss $8.3 Mln Or $0.39/Shr Last Year   RTTNews
07:07AM EDT  Earnings Scheduled For March 18, 2021   Benzinga
07:04AM EDT  Galmed Pharmaceuticals Q4 EPS $(0.48) Misses $(0.36) Estimate   Benzinga
07:01AM EDT  Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and   PR Newswire
Mar 16, 2021
08:10AM EDT  Galmed Pharma Doses First Subject In First In Human Phase 1 Trial Of Amilo-5MER For Chronic Inflammatory Diseases   RTTNews
08:02AM EDT  Galmed Pharmaceuticals Announces Dosing Of First Subject In First In Human Phase 1 Trial Of Amilo-5MER   Benzinga
08:02AM EDT  Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human   PR Newswire
Mar 14, 2021
08:14AM EDT  Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations   Benzinga
Mar 11, 2021
08:31AM EST  Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial   PR Newswire
Feb 16, 2021
09:32AM EST  Galmed Pharmaceuticals Prices $10 Mln Public Offering Of Ordinary Shares   RTTNews
09:32AM EST  Galmed Pharma Prices ~2.198M Share Offering For Gross Proceeds $10M   Benzinga
09:30AM EST  Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of   PR Newswire
06:50AM EST  Galmed Pharmaceuticals Announces Proposed Offering Of Ordinary Shares; Size Not Disclosed   Benzinga
06:49AM EST  Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares   PR Newswire
Jan 26, 2021
08:10AM EST  Galmed Pharma Highlights Upcoming Presentation In Journal Of High Energy Physics Reports On New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism Of Action   Benzinga
08:02AM EST  Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New   PR Newswire
Jan 19, 2021
08:01AM EST  Galmed Hosting KOL Symposium and Pipeline Update   PR Newswire
Jan 8, 2021
11:02AM EST  Raymond James Maintains Outperform on Galmed Pharmaceuticals, Lowers Price Target to $17   Benzinga
Dec 17, 2020
08:10AM EST  Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021   PR Newswire
Nov 25, 2020
11:07AM EST  Canaccord Genuity Maintains Buy on Galmed Pharmaceuticals, Lowers Price Target to $20   Benzinga
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
07:32AM EST  Galmed Pharma Q3 Net Loss $6.9 Mln Or $0.32/Shr Vs Loss Of $4.5 Mln Or $0.21/Shr Last Year   RTTNews
07:07AM EST  Galmed Pharmaceuticals Q3 EPS $(0.32) Misses $(0.30) Estimate   Benzinga
07:01AM EST  Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results   PR Newswire
04:18AM EST  Earnings Scheduled For November 12, 2020   Benzinga
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 9, 2020
08:15AM EST  Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol   Benzinga
08:14AM EST  Galmed, MyBiotics To Collaborate To Develop Bespoke Microbiome Signature For Aramchol   RTTNews
08:01AM EST  Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome   PR Newswire
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
08:31AM EST  Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and   PR Newswire
Sep 10, 2020
09:23AM EDT  Galmed, Gannex Expand Development Programs For NASH Through Research Collaboration Of Aramchol And ASC41   RTTNews
08:50AM EDT  Galmed And Gannex Expand Development Programs For NASH Through Research Collaboration Of Aramchol And ASC41 (   Benzinga
08:50AM EDT  Galmed and Gannex Expand Development Programs For NASH Through Research   PR Newswire
Sep 9, 2020
06:35AM EDT  Ascletis Pharma, Galmed Pharma Enter Deal Aiming At Combination Therapy Of ASC41 And Aramchol For The Treatment Of NASH   RTTNews
06:33AM EDT  Gannex And Galmed Announce Research Collaboration For Aramchol And ASC41   Benzinga
Aug 6, 2020
08:57AM EDT  Galmed Pharmaceuticals Earlier Reported Q2 EPS $(0.26) Beats $(0.32) Estimate   Benzinga
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
07:26AM EDT  Galmed Pharma Q2 Net Loss $5.5 Mln Or $0.26/shr Vs Net Loss $4.2 Mln Or $0.20/shr Last Year   RTTNews
07:01AM EDT  Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020   PR Newswire
06:50AM EDT  Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER   PR Newswire
Jul 30, 2020
08:31AM EDT  Galmed Pharmaceuticals to Report Second Quarter 2020 Financial Results and   PR Newswire
Jul 17, 2020
05:08AM EDT  64 Biggest Movers From Yesterday   Benzinga
Jul 15, 2020
10:09AM EDT  Shares of Galmed Pharmaceuticals Ltd. (GLMD) have been trading between $3.02 and $7.38 in the past one year, with trading volume of 251K shares versus an average volume of 70K shares.   RTTNews


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC